#1 Clinical Trials Search in Europe

Naporafenib

Naporafenib, also known as ERAS-254 or LXH254, is an experimental Pan-Raf inhibitor being studied in clinical trials for the treatment of advanced or metastatic solid tumors and NRAS-mutant melanoma. These trials aim to evaluate the safety, efficacy, and potential benefits of combining Naporafenib with other drugs, particularly Trametinib, in patients who have not responded to standard therapies or for whom no standard therapy exists.

Table of Contents

What is Naporafenib?

Naporafenib, also known as ERAS-254 or LXH254, is an experimental cancer medication currently being studied in clinical trials[1][2]. It belongs to a class of drugs called Pan-Raf inhibitors, which means it targets specific proteins in cancer cells that are involved in cell growth and division[1].

How Does Naporafenib Work?

Naporafenib works by inhibiting (blocking) a group of proteins called RAF proteins. These proteins are part of a signaling pathway in cells called the MAPK pathway, which is often overactive in cancer cells, causing them to grow and divide uncontrollably. By blocking these proteins, naporafenib aims to slow down or stop the growth of cancer cells[1].

In the clinical trials, naporafenib is being studied in combination with another drug called trametinib. Trametinib is an FDA-approved cancer medication that targets different proteins (MEK1 and MEK2) in the same MAPK pathway. The combination of these two drugs is hoped to provide a more effective treatment by blocking the cancer-promoting pathway at multiple points[1][2].

What Conditions Does Naporafenib Treat?

Naporafenib is being studied for the treatment of several types of advanced or metastatic solid tumors. Specifically, it’s being investigated for:

  • Advanced or metastatic solid tumors with RAS Q61X mutations: These are cancers that have spread to other parts of the body and have a specific genetic mutation in the RAS gene[1].
  • Advanced or metastatic NRAS-mutant melanoma: This is a type of skin cancer that has spread and has a mutation in the NRAS gene[2].

It’s important to note that naporafenib is not yet approved for general use and is only available through clinical trials at this time.

How is Naporafenib Administered?

In the clinical trials, naporafenib is being administered orally (by mouth) in the form of tablets. The dosage being studied is 200 mg twice daily, although other dosages are also being explored[1][2]. It’s typically given in combination with trametinib, which is taken once daily.

Clinical Trials Involving Naporafenib

There are currently two major clinical trials studying naporafenib:

  1. SEACRAFT-1: This is an open-label study assessing the safety and efficacy of naporafenib combined with trametinib in patients with advanced solid tumors that have RAS Q61X mutations. The study aims to enroll about 115 patients, including both adults and adolescents[1].
  2. SEACRAFT-2: This is a larger, Phase III randomized study comparing the combination of naporafenib and trametinib to standard treatments (physician’s choice of dacarbazine, temozolomide, or trametinib alone) in patients with NRAS-mutant melanoma. This study plans to enroll about 470 patients[2].

These trials are looking at several outcomes, including how well the treatment works (efficacy), how safe it is (side effects), and how the body processes the drug (pharmacokinetics)[1][2].

Potential Side Effects

As naporafenib is still in clinical trials, the full range of potential side effects is not yet known. The trials are closely monitoring for any adverse events (side effects) that may occur. Common side effects of cancer treatments can include fatigue, nausea, and changes in appetite, but the specific side effects of naporafenib will be better understood as the trials progress[1][2].

Future Prospects

The development of naporafenib represents an exciting advancement in targeted cancer therapy. If the clinical trials show positive results, naporafenib could potentially offer a new treatment option for patients with certain types of advanced cancers, particularly those with specific genetic mutations[1][2].

However, it’s important to remember that naporafenib is still in the experimental stage. More research is needed to fully understand its effectiveness and safety profile. Patients interested in this treatment should discuss with their healthcare provider whether participating in a clinical trial might be appropriate for their individual situation.

Aspect Details
Drug Name Naporafenib (ERAS-254, LXH254)
Drug Type Experimental Pan-Raf inhibitor
Administration Oral, twice daily
Combination Therapy Primarily studied with Trametinib
Target Conditions Advanced or metastatic solid tumors with RAS Q61X mutations, NRAS-mutant melanoma
Key Outcomes Measured Safety, efficacy, tumor response, survival rates, quality of life
Trial Phases Phase III (SEACRAFT-2 study)
Comparison Treatments Dacarbazine, Temozolomide, Trametinib monotherapy
Patient Population Adults and adolescents (≥12 years) with specific cancer types

FAQ

  • What is Naporafenib and how does it work? Naporafenib (ERAS-254) is an experimental Pan-Raf inhibitor. It works by targeting and inhibiting the Raf proteins, which are involved in cell growth and division. By blocking these proteins, Naporafenib may help slow down or stop the growth of cancer cells.
  • What types of cancer is Naporafenib being studied for? Naporafenib is being studied for advanced or metastatic solid tumors with RAS Q61X mutations and NRAS-mutant melanoma. These are cancers that have spread to other parts of the body or cannot be surgically removed.
  • How is Naporafenib administered in these clinical trials? In the clinical trials, Naporafenib is administered orally (by mouth) twice daily. The exact dosage may vary depending on the specific trial and combination with other drugs.
  • What other drugs is Naporafenib being combined with in these trials? Naporafenib is primarily being studied in combination with Trametinib, an FDA-approved anticancer medication that targets MEK1 and MEK2 proteins. This combination is being compared to other treatments like dacarbazine, temozolomide, or Trametinib alone.
  • What are the main goals of these clinical trials involving Naporafenib? The main goals of these trials are to evaluate the safety and efficacy of Naporafenib, determine the optimal dosage, assess its effects on tumor growth and patient survival, and compare its performance to existing treatments. The trials also aim to understand how the drug behaves in the body and its impact on patients' quality of life.

Ongoing Clinical Trials on Naporafenib

  • Study Comparing Naporafenib and Trametinib Combination to Other Therapies for Patients with Previously Treated Unresectable or Metastatic NRAS Mutant Melanoma

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Belgium Czechia Denmark France Germany Italy +4

  • Study on the Safety and Tolerability of Spartalizumab for Patients with Advanced Cancer

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Czechia France Germany Hungary Italy +2

  • Study on the Effectiveness and Safety of Naporafenib Combinations in Patients with Previously Treated Unresectable or Metastatic Melanoma

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany Italy

Glossary

  • Pan-Raf inhibitor: A type of drug that blocks the activity of all RAF proteins, which are involved in cell growth and division. In cancer, these proteins can become overactive, leading to uncontrolled cell growth.
  • RAS Q61X mutations: Specific changes in the RAS gene that can lead to the development of cancer. The 'Q61X' refers to a particular location in the gene where the mutation occurs.
  • NRAS-mutant melanoma: A type of skin cancer that has a mutation in the NRAS gene, which is involved in cell growth and division.
  • Metastatic: Cancer that has spread from its original site to other parts of the body.
  • Trametinib: An FDA-approved anticancer medication that targets proteins called MEK1 and MEK2, which are involved in cell growth and division.
  • Pharmacokinetic (PK) profile: The way a drug moves through the body, including how it's absorbed, distributed, metabolized, and eliminated.
  • RECIST: Response Evaluation Criteria in Solid Tumors, a standard way to measure how well a cancer patient responds to treatment.
  • Progression Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it getting worse.
  • Overall Survival (OS): The length of time from the start of treatment that patients are still alive.
  • Adverse Events (AEs): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.

References